NASDAQ$MCRB
Seres Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fourth quarter and full year 2023 financial results and provided business updates.
Seres Therapeutics reported VOWST net sales of $10.4 million for the fourth quarter of 2023. The company's net loss for the quarter was $41.2 million, as compared to a net loss of $68.8 million for the same period in 2022.
- VOWST net sales were $10.4 million for the fourth quarter of 2023.
- 2,833 patient enrollment forms received and 2,015 new patient starts since VOWST launch in June through year-end 2023.
- SER-155 Phase 1b placebo-controlled Cohort 2 clinical data anticipated in third quarter of 2024.
- Named to “TIME 100 Most Influential Companies” list.
Headline financials
Revenue & EPS history
Seres Therapeutics · Revenue · Quarterly
$64K
Forward guidance
Seres anticipates that its year-end cash balance, in conjunction with the planned savings from the restructuring announced in November 2023 and, assuming continued quarter-over-quarter revenue growth of VOWST, the expected receipt of the $45 million Tranche B will support its operations into the fourth quarter of 2024.
Tailwinds
- Expansion of the number of HCPs prescribing VOWST as a result of new efforts scaled by Nestlé Health Science in Q4 2023 such as strengthened promotional campaigns and expanded reach of digital promotion.
- Increase VOWST utilization earlier in the treatment paradigm including in patients experiencing their first recurrence.
- Maintenance of strong patient access and expansion of payer coverage for VOWST across Commercial and Medicare Part D plans.
- Increase penetration of the hospital outflow patient segment.
- SER-155 Phase 1b placebo-controlled Cohort 2 data readout anticipated in third quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+9.8%
Avg return
30 days after
44%
19 / 43 earnings
Positive
+29.9%
Q4 2016
Best reaction
-17.6%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.1% | +0.5% | -10.6% | |
| Q4 2025 | -4.4% | +5.1% | -6.8% | |
| Q3 2025 | -8.4% | +2.2% | +21.2% | |
| Q1 2025 | -3.7% | -7.8% | -3.7% | |
| Q4 2024 | -7.9% | +7.8% | -14.7% | |
| Q3 2024 | -10.8% | -12.8% | +32.4% | |
| Q2 2024 | +1.5% | -1.1% | +7.9% | |
| Q1 2024 | -7.2% | -13.1% | -44.7% | |
| Q4 2023 | -11.4% | -14.8% | -33.8% | |
| Q3 2023 | -9.7% | -15.3% | -25.7% | |
| Q2 2023 | -12.6% | -16.1% | -29.7% | |
| Q1 2023 | -4.5% | -7.7% | +0.7% | |
| Q4 2022 | +8.2% | -4.2% | +5.1% | |
| Q3 2022 | -0.7% | -13.1% | -21.2% | |
| Q2 2022 | +19.0% | +18.3% | +31.5% | |
| Q1 2022 | -10.1% | -22.7% | -30.4% | |
| Q4 2021 | -7.3% | -21.3% | -11.0% | |
| Q3 2021 | +10.3% | +13.7% | +39.3% | |
| Q2 2021 | +0.9% | -0.7% | -3.8% | |
| Q1 2021 | +3.8% | +1.9% | -9.3% | |
| Q4 2020 | -14.4% | -7.6% | -0.8% | |
| Q3 2020 | -3.9% | -0.4% | -31.0% | |
| Q2 2020 | -3.1% | -11.0% | +488.1% | |
| Q1 2020 | +21.1% | +29.5% | +23.2% | |
| Q4 2019 | +7.3% | +12.1% | +4.8% | |
| Q3 2019 | -2.1% | -2.9% | -3.2% | |
| Q2 2019 | +5.3% | +10.2% | +42.2% | |
| Q1 2019 | -17.5% | -20.1% | -44.2% | |
| Q4 2018 | -17.6% | +0.5% | +1.3% | |
| Q3 2018 | +3.8% | +0.0% | -5.4% | |
| Q2 2018 | +1.6% | +2.8% | +18.2% | |
| Q1 2018 | -0.7% | +0.0% | +0.4% | |
| Q4 2017 | -4.0% | -6.2% | -26.5% | |
| Q3 2017 | +4.1% | +0.8% | +6.5% | |
| Q2 2017 | +2.8% | +1.8% | +4.1% | |
| Q1 2017 | +2.3% | +1.6% | -2.6% | |
| Q4 2016 | +29.9% | +19.7% | +14.6% | |
| Q3 2016 | +8.2% | +8.9% | -14.1% | |
| Q2 2016 | +14.3% | +21.0% | +13.5% | |
| Q1 2016 | +6.5% | — | — | |
| Q4 2015 | +0.9% | — | — | |
| Q3 2015 | -2.1% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro